An announcement from Telix Pharmaceuticals Ltd. ( (AU:TLX) ) is now available.
Telix Pharmaceuticals announced that its CEO, Dr. Christian Behrenbruch, plans to sell 2,000,000 shares, representing less than 10% of his holdings, for personal reasons related to a divorce settlement and estate planning. The sale, approved by the Board, will occur after the company’s annual financial results release, and Dr. Behrenbruch has committed to a twelve-month lock-up period prohibiting further sales. This move is not expected to impact his commitment to the company, as he remains a major shareholder with approximately 6.30% of Telix’s issued capital.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and related medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Canada, Europe, and Japan, focusing on addressing significant unmet medical needs in oncology and rare diseases.
YTD Price Performance: 42.51%
Average Trading Volume: 4,631
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.48B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.